ENLIVEN THERAPEUTICS, INC.: stockholders equity
Stockholders equity for ENLIVEN THERAPEUTICS, INC. Inspect selected reporting periods, original units and SEC filing links; download the financial history.
All ENLIVEN THERAPEUTICS, INC. financial histories
What this measure means
The reported residual interest after liabilities. It is an accounting amount, not market capitalization.
Exact concept: us-gaap:StockholdersEquity. Each value is a balance at the reporting date, not a flow earned over a year. Different units remain separate; no currency conversion or interpolation is applied.
Coverage of this history
Selected reporting periods run from 2018-12-31 to 2025-12-31. The SEC response was captured on 2026-09-21.
Selected filing history
| Period start | Period end | Value | Unit | Filed | Source filing |
|---|---|---|---|---|---|
| At date | 2025-12-31 | 459,600,000 | USD | 2026-03-03 | 10-K · 0001193125-26-088232 |
| At date | 2024-12-31 | 309,845,000 | USD | 2026-03-03 | 10-K · 0001193125-26-088232 |
| At date | 2023-12-31 | 245,906,000 | USD | 2026-03-03 | 10-K · 0001193125-26-088232 |
| At date | 2022-12-31 | -76,825,000 | USD | 2025-03-13 | 10-K · 0000950170-25-038758 |
| At date | 2021-12-31 | -42,887,000 | USD | 2024-03-14 | 10-K · 0000950170-24-031495 |
| At date | 2020-12-31 | 84,435,000 | USD | 2023-02-10 | 10-K · 0001564590-23-001729 |
| At date | 2019-12-31 | -48,848,000 | USD | 2022-03-15 | 10-K · 0001564590-22-010216 |
| At date | 2018-12-31 | -26,316,000 | USD | 2021-03-05 | 10-K · 0001564590-21-011098 |
Related financial histories
- ENLIVEN THERAPEUTICS, INC.: total assets
- ENLIVEN THERAPEUTICS, INC.: total liabilities
- ENLIVEN THERAPEUTICS, INC.: cash and cash equivalents
- ENLIVEN THERAPEUTICS, INC.: net income or loss
- ENLIVEN THERAPEUTICS, INC.: operating cash flow
- ENLIVEN THERAPEUTICS, INC.: financing cash flow
- ENLIVEN THERAPEUTICS, INC.: investing cash flow
- ENLIVEN THERAPEUTICS, INC.: retained earnings or deficit
- ENLIVEN THERAPEUTICS, INC.: basic weighted-average shares
- ENLIVEN THERAPEUTICS, INC.: diluted weighted-average shares
- ENLIVEN THERAPEUTICS, INC.: basic earnings per share
- ENLIVEN THERAPEUTICS, INC.: diluted earnings per share
- ENLIVEN THERAPEUTICS, INC.: income tax expense or benefit
- ENLIVEN THERAPEUTICS, INC.: net property, plant and equipment
- ENLIVEN THERAPEUTICS, INC.: share-based compensation expense
- ENLIVEN THERAPEUTICS, INC.: operating income or loss
- ENLIVEN THERAPEUTICS, INC.: current assets
- ENLIVEN THERAPEUTICS, INC.: current liabilities
- ENLIVEN THERAPEUTICS, INC.: current accounts payable
- ENLIVEN THERAPEUTICS, INC.: operating expenses
- ENLIVEN THERAPEUTICS, INC.: research and development expense
Inspect the source
- Entity
- ENLIVEN THERAPEUTICS, INC. / CIK 0001672619
- Captured
- 2026-09-21T17:23:22.950Z
- SEC response SHA-256
dc5c702d1320277637a883b71956720b0deb606fe497a659bf5d0985e324816d
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001672619.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))